181 related articles for article (PubMed ID: 36760377)
21. Dasatinib-induced pleural effusion: Chylothorax, an option to consider.
Ferreiro L; San-José E; Suárez-Antelo J; Valdés L
Ann Thorac Med; 2016; 11(4):289-293. PubMed ID: 27803756
[TBL] [Abstract][Full Text] [Related]
22. Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine "Goreisan".
Sasaki H; Kimizuka Y; Ogata H; Okada Y; Ota S; Sano T; Watanabe C; Maki Y; Yamamoto T; Tagami Y; Miyata J; Hayashi N; Fujikura Y; Kawana A
Intern Med; 2019 Nov; 58(21):3139-3141. PubMed ID: 31292394
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.
McCafferty EH; Dhillon S; Deeks ED
Paediatr Drugs; 2018 Dec; 20(6):593-600. PubMed ID: 30465234
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy.
Yassin MA; Nashwan AJ; Soliman AT; Yousif A; Moustafa A; AlBattah A; Mohamed SF; Mudawi DS; Elkourashy S; Asaari DR; Gutierrez HL; Almusharaf M; Hussein RM; Moustafa AH; Derhoubi HE; Boukhris S; Kohla S; AlDewik N
Clin Med Insights Case Rep; 2015; 8():77-81. PubMed ID: 26379451
[TBL] [Abstract][Full Text] [Related]
25. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
26. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
27. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jabbour E; Lipton JH
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
[TBL] [Abstract][Full Text] [Related]
28. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
29. Nilotinib rapidly reverses breakpoint cluster region-Abelson oncogene fusion gene and M244V mutations in a patient with chronic myelogenous leukemia: A case report.
Shen X; Zhang M; Shen Y; Shi W; Liu W; Wei WU
Exp Ther Med; 2015 Oct; 10(4):1479-1482. PubMed ID: 26622510
[TBL] [Abstract][Full Text] [Related]
30. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Wong SF
J Oncol Pharm Pract; 2009 Mar; 15(1):17-27. PubMed ID: 18753186
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib.
Lindauer M; Hochhaus A
Recent Results Cancer Res; 2018; 212():29-68. PubMed ID: 30069624
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Jabbour E; Cortes J; Kantarjian H
Cancer; 2011 Mar; 117(5):897-906. PubMed ID: 20945321
[TBL] [Abstract][Full Text] [Related]
36. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib-Induced Chylothorax: A Clinical Laboratory's Perspective.
Martínez RJG; Gea CS; Martin-Riera V; Ruiz ARG; Barzanti RP; Ferrer-Costa R; Ramirez-Serra C
EJIFCC; 2023 Apr; 34(1):76-80. PubMed ID: 37124659
[TBL] [Abstract][Full Text] [Related]
39. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Maral S; Bakanay SM; Kucuksahin O; Dilek I
J Oncol Pharm Pract; 2020 Apr; 26(3):738-741. PubMed ID: 31359838
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]